---
{"dg-publish":true,"permalink":"/5//asco-2024-68-ga-psma-petct-response-and-clinical-outcomes-in-patients-treated-with-enzalutamide-as-first-line-therapy-for-metastatic-castration-resistant-prostate-cancer-results-of-a-prospective-study/","tags":["gardenEntry"]}
---

# ASCO 2024ï¼šé’ˆå¯¹è½¬ç§»æ€§å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œä¸€çº¿ä½¿ç”¨æ©æ‚é²èƒºæ²»ç–—æ‚£è€…çš„68Ga-PSMA PET/CTååº”ä¸ä¸´åºŠç»“å±€ï¼šä¸€é¡¹å‰ç»æ€§ç ”ç©¶çš„ç»“æœ

---
### æ¦‚è¿°
åœ¨2024å¹´ç¾å›½ä¸´åºŠè‚¿ç˜¤å­¦ä¼šï¼ˆASCOï¼‰å¹´ä¼šä¸Šï¼Œå±•ç¤ºäº†ä¸€é¡¹å…³äº68Ga-PSMA PET/CTååº”ä¸è½¬ç§»æ€§å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œï¼ˆmCRPCï¼‰æ‚£è€…æ¥å—æ©æ‚é²èƒºä¸€çº¿æ²»ç–—çš„ä¸´åºŠç»“æœçš„å‰ç»æ€§ç ”ç©¶ã€‚

### äº®ç‚¹
- ğŸ§ª **ç ”ç©¶èƒŒæ™¯**ï¼šæœ¬ç ”ç©¶è¯„ä¼°äº†68Ga-PSMA PET/CTåœ¨æ¥å—ç³»ç»Ÿæ²»ç–—çš„mCRPCæ‚£è€…ä¸­çš„ååº”è¯„ä¼°ä½œç”¨ã€‚
- ğŸ’Š **æ²»ç–—æ–¹æ³•**ï¼š70åè¿ç»­çš„mCRPCæ‚£è€…æ¯å¤©æœç”¨160 mgæ©æ‚é²èƒºï¼Œå¹¶åœ¨æ²»ç–—å‰åä¸‰å‘¨å†…è¿›è¡Œäº†68Ga-PSMA PET/CTã€‚
- ğŸ“Š **è¯„ä¼°å‚æ•°**ï¼šç ”ç©¶è¯„ä¼°äº†ä»£è°¢æ€»é‡ã€æ ‡å‡†æ‘„å–å€¼å’Œæ€»ç—…ç¶æ´»æ€§ç­‰å‚æ•°ã€‚
- ğŸ” **åˆ†ç±»æ ‡å‡†**ï¼šæ ¹æ®EAU/EANMæ ‡å‡†ï¼Œå°†æ‚£è€…åˆ†ä¸ºPETå“åº”è€…å’Œéå“åº”è€…ï¼ŒåŸºäºPSAæ°´å¹³åˆ†ç±»ä¸ºç”ŸåŒ–å“åº”è€…å’Œéå“åº”è€…ã€‚
- â³ **ç”Ÿå­˜åˆ†æ**ï¼šä½¿ç”¨Coxå›å½’é£é™©æ¨¡å‹å’ŒKaplan-Meieræ³•è¿›è¡Œç”Ÿå­˜åˆ†æï¼Œä¸­ä½æ— è¿›å±•ç”Ÿå­˜æœŸå’Œä¸­ä½æ€»ä½“ç”Ÿå­˜æœŸåˆ†åˆ«ä¸º36.7ä¸ªæœˆå’Œ66.5ä¸ªæœˆã€‚
- ğŸ“ˆ **ç ”ç©¶ç»“æœ**ï¼šæ€»ç—…ç¶æ´»æ€§åœ¨12å‘¨æ—¶æ˜¾è‘—ä¸ä¸­ä½æ— è¿›å±•ç”Ÿå­˜æœŸå’Œä¸­ä½æ€»ä½“ç”Ÿå­˜æœŸç›¸å…³ã€‚
- ğŸ“ **ç»“è®º**ï¼š68Ga-PSMA PET/CTæ¯”PSAç›‘æµ‹æ›´èƒ½é¢„æµ‹æ¥å—æ©æ‚é²èƒºæ²»ç–—çš„mCRPCæ‚£è€…çš„æ— è¿›å±•ç”Ÿå­˜æœŸã€‚

### é…å›¾


1. ![å›¾ç‰‡1](https://proxy-prod.omnivore-image-cache.app/624x138,sZxrkCFUsIepkuOyFS69a9Iz374rguNDtL3NiP3JpLMc/https://www.urotoday.com/images/com-doc-importer/164-asco-2024/asco-2024-68ga-psma-pet-ct-response-and-clinical-outcomes-in-patients-treated-with-enzalutamide-as-first-line-therapy-for-metastatic-castration-resistant-prostate-cancer-mcrpc-results-of-a-prospective-study/image-0.jpg)
   - è¯´æ˜ï¼šå±•ç¤ºäº†ç ”ç©¶ä¸­ä½¿ç”¨çš„68Ga-PSMA PET/CTæ‰«æå›¾åƒã€‚

2. ![å›¾ç‰‡2](https://proxy-prod.omnivore-image-cache.app/624x390,sl42ExVDSUJGwUpN7j6qzQ0ddoQ1CHW5zhLd1H37ec7c/https://www.urotoday.com/images/com-doc-importer/164-asco-2024/asco-2024-68ga-psma-pet-ct-response-and-clinical-outcomes-in-patients-treated-with-enzalutamide-as-first-line-therapy-for-metastatic-castration-resistant-prostate-cancer-mcrpc-results-of-a-prospective-study/image-1.jpg)
   - è¯´æ˜ï¼šæ˜¾ç¤ºäº†mCRPCæ‚£è€…çš„ä¸´åºŠç‰¹å¾ç»Ÿè®¡å›¾ã€‚

3. ![å›¾ç‰‡3](https://proxy-prod.omnivore-image-cache.app/624x374,selEhXImYJEqWXN_RCrkH1FoSC8bfpmjI80TieZqFDcY/https://www.urotoday.com/images/com-doc-importer/164-asco-2024/asco-2024-68ga-psma-pet-ct-response-and-clinical-outcomes-in-patients-treated-with-enzalutamide-as-first-line-therapy-for-metastatic-castration-resistant-prostate-cancer-mcrpc-results-of-a-prospective-study/image-2.jpg)
   - è¯´æ˜ï¼šå±•ç¤ºäº†PSAå’ŒPSMA PETå“åº”ä¹‹é—´çš„ä¸€è‡´æ€§å’Œä¸ä¸€è‡´æ€§çš„åˆ—è”è¡¨ã€‚

4. ![å›¾ç‰‡4](https://proxy-prod.omnivore-image-cache.app/624x173,s5f9Y5b2OR5kP0DA1nd1M-W6n0NgN2I9hur-dWNOe8O4/https://www.urotoday.com/images/com-doc-importer/164-asco-2024/asco-2024-68ga-psma-pet-ct-response-and-clinical-outcomes-in-patients-treated-with-enzalutamide-as-first-line-therapy-for-metastatic-castration-resistant-prostate-cancer-mcrpc-results-of-a-prospective-study/image-3.jpg)
   - è¯´æ˜ï¼šå±•ç¤ºäº†æ•°æ®åˆ†æç»“æœï¼Œå°¤å…¶æ˜¯ä¸åŒå“åº”ç»„çš„æ— è¿›å±•ç”Ÿå­˜æœŸï¼ˆmPFSï¼‰å’Œæ€»ä½“ç”Ÿå­˜æœŸï¼ˆmOSï¼‰ã€‚

5. ![å›¾ç‰‡5](https://proxy-prod.omnivore-image-cache.app/624x247,sYGeDMWK2Jx10oFToXuo-2SxHG2R9mjQIoejWHQ4kfr0/https://www.urotoday.com/images/com-doc-importer/164-asco-2024/asco-2024-68ga-psma-pet-ct-response-and-clinical-outcomes-in-patients-treated-with-enzalutamide-as-first-line-therapy-for-metastatic-castration-resistant-prostate-cancer-mcrpc-results-of-a-prospective-study/image-4.jpg)
   - è¯´æ˜ï¼šå¤šå˜é‡åˆ†æç»“æœï¼Œæ˜¾ç¤º12å‘¨æ—¶æ€»ç—…ç¶æ´»æ€§ä¸ä¸­ä½æ— è¿›å±•ç”Ÿå­˜æœŸå’Œä¸­ä½æ€»ä½“ç”Ÿå­˜æœŸæ˜¾è‘—ç›¸å…³ã€‚

### ç›¸å…³é—®é¢˜

#### è¯¥ç ”ç©¶çš„ç›®çš„æ˜¯ä»€ä¹ˆï¼Ÿ

è¯¥ç ”ç©¶çš„ç›®çš„æ˜¯è¯„ä¼°68Ga-PSMA PET/CTå“åº”ä¸ä¸´åºŠç»“æœåœ¨æ¥å—ç¬¬ä¸€çº¿enzalutamideæ²»ç–—çš„è½¬ç§»æ€§å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œï¼ˆmCRPCï¼‰æ‚£è€…ä¹‹é—´çš„å…³è”ã€‚ç ”ç©¶æ—¨åœ¨æ¯”è¾ƒ68Ga-PSMA PET/CTå“åº”ä¸å‰åˆ—è…ºç‰¹å¼‚æ€§æŠ—åŸï¼ˆPSAï¼‰å“åº”åœ¨mCRPCæ‚£è€…æ¥å—enzalutamideä½œä¸ºç¬¬ä¸€çº¿æ²»ç–—æ—¶çš„å½±å“ã€‚

#### ç ”ç©¶ç»“æœæ˜¾ç¤ºä»€ä¹ˆï¼Ÿ

ç ”ç©¶ç»“æœæ˜¾ç¤ºï¼Œåœ¨mCRPCæ‚£è€…æ¥å—ç¬¬ä¸€çº¿enzalutamideæ²»ç–—åï¼Œé€šè¿‡è¯„ä¼°68Ga-PSMA PET/CTå“åº”ä¸PSAå“åº”çš„å…³è”ï¼Œå‘ç°PSAç›‘æµ‹ç›¸å¯¹äº68Ga-PSMA PET/CTå“åº”æ¥é¢„æµ‹è¿›å±•ç”Ÿå­˜çš„èƒ½åŠ›è¾ƒå¼±ã€‚ç ”ç©¶è¿˜è¡¨æ˜ï¼Œä¸€äº›PETå‚æ•°å¯èƒ½æ›´å¥½åœ°é¢„æµ‹ç”Ÿå­˜ç›Šå¤„ï¼Œä½†éœ€è¦æœªæ¥çš„éªŒè¯ã€‚

#### å¯¹äºmCRPCæ‚£è€…ï¼ŒPSAç›‘æµ‹å’Œ68Ga-PSMA PET/CTå“ªä¸ªæ›´å…·é¢„æµ‹è¿›å±•ç”Ÿå­˜çš„èƒ½åŠ›ï¼Ÿ

æ ¹æ®è¯¥ç ”ç©¶çš„ç»“æœï¼Œå¯¹äºmCRPCæ‚£è€…ï¼Œç ”ç©¶è¡¨æ˜68Ga-PSMA PET/CTå“åº”ç›¸å¯¹äºPSAç›‘æµ‹æ›´å…·é¢„æµ‹è¿›å±•ç”Ÿå­˜çš„èƒ½åŠ›ã€‚ç ”ç©¶å‘ç°ï¼ŒPSAç›‘æµ‹ç›¸å¯¹äº68Ga-PSMA PET/CTå“åº”æ¥é¢„æµ‹è¿›å±•ç”Ÿå­˜çš„èƒ½åŠ›è¾ƒå¼±ï¼Œå› æ­¤ï¼Œ68Ga-PSMA PET/CTå¯èƒ½æ›´é€‚åˆç”¨äºè¯„ä¼°mCRPCæ‚£è€…çš„æ²»ç–—ååº”å’Œé¢„æµ‹ç”Ÿå­˜ã€‚

#### åœ¨ç ”ç©¶ä¸­ï¼Œå“ªäº›PETå‚æ•°å¯èƒ½æ›´å¥½åœ°é¢„æµ‹ç”Ÿå­˜ç›Šå¤„ï¼Ÿ

åœ¨ç ”ç©¶ä¸­ï¼Œç ”ç©¶äººå‘˜å‘ç°æ€»ç—…ç¶æ´»æ€§ï¼ˆtotal lesion activityï¼‰åœ¨12å‘¨æ—¶ä¸ä¸­ä½æ— è¿›å±•ç”Ÿå­˜ï¼ˆmedian progression-free survivalï¼‰å’Œä¸­ä½æ€»ç”Ÿå­˜ï¼ˆmedian overall survivalï¼‰æ˜¾è‘—ç›¸å…³ã€‚è¿™è¡¨æ˜æ€»ç—…ç¶æ´»æ€§å¯èƒ½æ˜¯æ›´å¥½åœ°é¢„æµ‹ç”Ÿå­˜ç›Šå¤„çš„PETå‚æ•°ä¹‹ä¸€ã€‚ç„¶è€Œï¼Œç ”ç©¶æŒ‡å‡ºè¿™äº›ç»“æœéœ€è¦æœªæ¥çš„éªŒè¯ã€‚